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RESUMEN
Introducción: El objetivo principal del presente estudio fue preparar y caracterizar la formulación lipo-
somal de baclofeno para mejorar la efectividad de la formulación aplicada tópicamente.
Método: Para la preparación de liposomas, se tomaron diferentes proporciones de lecitina, colesterol y 
etanol, pero la proporción de fármaco y ácido esteárico se mantuvo constante y se preparó mediante el 
método de inyección de etanol. Los liposomas se caracterizaron por tamaño de vesícula, forma de vesí-
cula, eficacia de atrapamiento, estudios in vitro, estudios de estabilidad y estudios in vivo.
Resultados: El tamaño promedio de partícula del liposoma formulado estuvo en el rango de 3.98 ± 
0,45-4,24 ± 0,65 µm y se observaron pequeñas vesículas unilamelares con forma esférica. La eficiencia de 
atrapamiento de la formulación optimizada fue de 58,67 ± 0,81%. El % máximo de comportamientos acu-
mulativos de liberación de drogas fue 67,66 ± 5,32% después de 10 h. la formulación almacenada a una 
temperatura de 4 ± 2 ° C muestra una mejor estabilidad (64,19±0,26) en comparación con la temperatura 
elevada. Se usaron ratones albinos suizos para el estudio in vivo y exhiben actividad relajante muscular 
en términos de no. de caídas del aparato de varilla giratoria (valor p = 0,001).
Conclusiones: la formulación liposomal cargada de baclofeno ha mostrado actividad relajante del mús-
culo esquelético en ratones, lo que sugiere la administración de baclofeno desde los liposomas en el 
rango terapéutico.
Palabras clave: Lecitina; colesterol; baclofeno; etanol; actividad relajante muscular.
ABSTRACT
Introduction: The main aim of present study was to prepare and characterize liposomal formulation of 
baclofen to improve the effectiveness of the topically applied formulation.
Method: For the preparation of liposomes, different ratio of lecithin, cholesterol and ethanol were taken 
but ratio of drug and stearic acid were kept constant and prepared by ethanol injection method. Lipos-
omes were characterized for vesicle size, vesicle shape, entrapment efficiency, in vitro studies, stability 
studies and in vivo studies.
Results: The average particle size of formulated liposome was in the range of 3.98±0.45-4.24±0.65 µm and 
small unilamellar vesicles with spherical in shape observed. Entrapment efficiency of optimized formu-
lation was 58.67±0.81 %. The maximum % cumulative drug release behaviours were 67.66±5.32 % after 
10 h. formulation stored in 4±2 °C temperature shows better stability (64.19±0.26) compared to elevated 
temperature. Swiss albino mice were used for the in vivo study and exhibit muscle relaxant activity in 
terms of no. of falls from rota rod apparatus (p value =0.001).
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Conclusions: Baclofen loaded liposomal formulation have shown 
skeletal muscle relaxant activity in mice suggesting delivery of ba-
clofen from liposomes in the therapeutic range.
Keywords: Lecithin; Cholesterol; Baclofen; Ethanol; Muscle Relax-
ant Activity.
INTRODUCTION
Liposomes are spherical, self-enclosed vesicles in which 
aqueous part is entirely enclosed by phospholipid bilayer 
and liposomes is amphiphilic in nature, means it possess 
both lipophilic and hydrophilic character(1). Liposomes are 
prepared from a variety of natural and synthetic phospho-
lipids, and considered as drug-carrying structures or vesi-
cles(2).
Liposomes, which are versatile, biodegradable, nontoxic 
phospholipid vesicles, are known to reduce toxicity asso-
ciated with many compounds including antitumor(3), anti-
biotics(4), and immunosuppressive agents(5).The reasons for 
using liposomes can be summarized as follows: liposomes 
can enhance cellular internalization of the drug; they can 
generally decrease unwanted systemic toxic effects; and 
they may increase drug solubility in biological fluids, mod-
ulating at the same time the drug release profile. Further-
more, in some case, the use of phospholipid vesicles to car-
ry the drug to target cells could possess specific release by 
passive or active targeting strategies(6).
Controlled drug release can be achieved by transdermal 
drug delivery systems (TDDS) which can deliver medi-
cines via the skin portal to systemic circulation at a prede-
termined rate over a prolonged period of time. TDDS has 
gained a lot of interest during the last decade as it offers 
many advantages over the conventional dosage forms and 
oral controlled release delivery systems notably avoidance 
of hepatic first pass metabolism, less frequency of admin-
istration, reduction in gastrointestinal side effects and im-
proves patient compliance(7,8).
Drug was chosen because of its low meting point, low par-
tition coefficients and optimum range of molecular weight 
which is prerequisite for development of transdermal drug 
delivery system(8).
Transdermal therapeutic systems are defined as a self-con-
tained, discrete dosage forms which, when applied to the 
intact skin, deliver the drug, through the skin at control rate 
to the systemic circulation. Transdermal formulation main-
tain drug concentration within the therapeutic window for 
prolong period of time ensuring that drug levels neither fall 
below the minimum effective concentration nor exceed the 
maximum effective concentration(9).
Baclofen (BCF) is a direct agonist at GABAB receptors. Ba-
clofen used to relax the muscle during the condition of 
muscle contraction(10). The purpose of the current study 
was to investigate the feasibility of liposomes to formulate 
the transdermal administration of baclofen.
MATERIALS AND METHODS
Baclofen was a provided as gift sample from Sun Pharma-
ceutical Industries Limited, India. Soya lecithin was pur-
chased from Acros Organics, New Delhi, India. Cholesterol 
was purchased from Sigma, USA. Stearic acid purchased 
from Research Lab, Mumbai India. Ethanol (AR), Methanol 
and Chloroform purchased from Merck, India. The all other 
materials used in this study were of analytical grade.
The baclofen liposomes prepared as per method report-
ed A. Kumar, et al., (2010) with slight modifications. For 
the preparation of liposome various formulations were 
prepared using different ratio of lecithin, cholesterol and 
ethanol but drug and stearic acid ratio kept constant (Table 
1). The lecithin, cholesterol, stearic acid and drug were dis-
solving in organic solvents (ethanol) and injected in to 10 
ml preheated PBS water at 55-65oC with continuous stirring 
at 500 rpm using magnetic stirrer. The solvent was evapo-
rated by heating so as to obtain drug loaded liposomes(11).
Table 1: Formula for preparation of baclofen liposomes
Formu-
lation 
Code
Drug 
(mg)
Leci-
thin 
(%)
Cho-
lesterol 
(mg)
Stearic 
Acid 
(mg)
Eth-
anol 
(%)
RLP1 10 1 30 10 5
RLP2 10 2 40 10 10
RLP3 10 3 50 10 15
RLP4 10 4 60 10 20
RLP5 10 4 50 10 25
CHARACTERIZATION
Vesicle size:
The size of liposomes was determined by using a film of 
vesicle dispersion, fixed with 10% w/v gelatin solution, 
was observed under a light microscope (BEM-21, Besto Mi-
croscope, India) fitted with an ocular micrometer and stage 
micrometer at a magnificationof 100X(12).
Vesicle shape:
Vesicles morphology of baclofen liposomes obtained from 
ethanol evaporation was determined using a photomicro-
scope (Nikon Model UFX-II, Japan) at 1000 x magnifica-
tion(12).
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Entrapment efficiency:
The lipoosomal dispersions were centrifuged (90 XL Ul-
tracentrifuge, Beckman, USA) at 10,000 × g for 20 min to 
separate unentrapped drug and washed with phosphate 
buffered saline (pH 7.4). The clear supernatant was analyz-
ed for baclofen by UV-spectrophotometer (Shimadzu UV-
1700, Japan) at 226 nm. The amount of entrapped drug was 
calculated using the following equation(13).
In vitro drug release study:
The liposomes encapsulating baclofen were separated by 
gel filtration on sephadex G-50 column which was kept in 
double distilled water for 10 h for swelling. Then the pre-
pared liposomal suspension (1mL) was placed on the top 
of the column and elution was carried out using normal sa-
line. The liposomes loaded with baclofen elutes out first as a 
slightly dense, white opalescent suspension, were followed 
by free drug. Separated liposomes were filled in a dialysis 
tube to which a dialysis sac was attached to either end. The 
dialysis tube was suspended in phosphate buffered saline 
(pH 7.4) at 37±2°C, stirred with a magnetic stirrer and sam-
ples were withdrawn at specific time intervals and analyz-
ed spectrophotometrically (λmax 226 nm). The volume was 
replenished with the same amount of fresh dissolution flu-
id each time to maintain the sink condition(14).
Stability studies:
The liposomal formulations were subjected to stability 
studies by storing at 4±2°C, 25±2°C and 37±2°C in ther-
mostatic oven for 6 month(15). Then drug content of all the 
formulations was determined in terms of % entrapment at 
reported temperature.
In vivo study:
The apparatus consists of a horizontal wooden rod or metal 
rod coated with rubber with 3 cm diameter attached to a 
motor with the speed adjusted to 30 rotations per minute. 
The rod is 40 cm in length and is divided into 3 sections 
by plastic discs, thereby allowing the simultaneous testing 
of 45 mice. The rod is in a height of about 50 cm above the 
table top in order to discourage the animals from jumping 
off the roller. Cages below the sections serve to restrict the 
movements of the animals when they fall from the roller. 
The experiments were performed on male Swiss albino 
mice weighing 20-25 g. The mice were trained to run on 
the rod rotating at a rate of 10 rpm for 3 days. Only those 
animals which have demonstrated their ability to remain 
on the revolving rod for at least 300 s were used for the test. 
Two or three trials were usually enough for the animals to 
learn this task. The formulation as well as plane drug was 
applied topically with the help of custom designed plastic 
ring. Then it was allowed to be in contact with mouse skin 
for 30 minutes to ensure proper absorption. The mice were 
placed for 5 min on the rotating rod. The number of falls 
from the roller during this time was counted. Diazepam 
(2 mg/kg, i.p.) was used as positive control(16). The data 
of number of falls were analyzed by one way ANOVA fol-
lowed by Student-Newman-Keuls test.
RESULTS AND DISCUSSION
Vesicle size:
Particle size determination of liposomes was performed by 
light microscope after storage. The size of different formu-
lations of baclofen liposome was found to be in the range of 
3.98±0.45-4.24±0.65 µm.
Vesicle shape:
The microscopic study of drug loaded liposomes shows 
that small unilamellar vesicles were formed by ethanol in-
jection method. Microscopic observations of the prepared 
liposome formulation confirmed the formation of spherical 
particles as shown in Figure 1.
Figure 1: Photomicrograph of baclofen liposome formulation 
(RLP5)
Entrapment efficiency:
The entrapment efficiency of all the baclofen liposome for-
mulations (RLP1, RLP2, RLP3, RLP4 and RLP5) was car-
ried. The formulation RLP5 of baclofen liposome shows 
maximum % entrapment efficiency (58.67±0.81 %) com-
pared to RLP1, RLP2, RLP3 and RLP4 formulations (Table 
2).There was increase in % entrapment efficiency was ob-
served with an increase in ethanol concentration.Improve-
ment in aqueous solubility of baclofen was achieved with 
higher concentration of ethanol, due to its co-solvent effect. 
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The % entrapment efficiency also increased with an in-
crease in concentration of lecithin.
Table 2: Effect of lipid content on drug entrapment efficiency 
(results are ±SD, n=3)
Formulation Code % EE
RLP1 40.13±0.41
RLP2 44.32±0.56
RLP3 50.63±0.15
RLP4 55.58±0.17
RLP5 58.67±0.81
In vitro drug release study:
The in vitro drug release study of baclofen liposomes for-
mulation was carried out up to 10 h in PBS (pH 7.4) at 
37±2°C. The formulation RLP5 of baclofen liposome shows 
maximum % cumulative drug release (67.66±5.32 %) com-
pared to RLP1, RLP2, RLP3 and RLP4 formulations (Ta-
ble 3). Formulation RLP5 shows maximum % cumulative 
drug release due to the maximum entrapment of drug in 
the vesicles. This was apparently low in magnitude (pure 
drug-about 92 % vs. RLP5-67 %) and released over longer 
period of time as compared to pure drug taken as standard. 
Therefore, the drug release could be said to be in sustained 
fashion. As the cholesterol ratio increased the % cumula-
tive drug release also increased but afterwards it shows di-
minished release of drug because vesicles consist of several 
concentric sphere of bilayer above the aqueous compart-
ment. Stearic acid also helps to promote the drug contents 
release from the vesicles because of its softening and lubri-
cating behaviors.
Table 3: Effect of cholesterol, lipid and stearic acid on in vitro% release profile of baclofen liposome in PBS 7.4 pH, 37±2°C at λ max 226 
nm (results are ±SD, n=3)
Time (h)
% Cumulative drug release
Pure drug* RLP1 RLP2 RLP3 RLP4 RLP5*
0 00±0.00 00±0.00 00±0.00 00±0.00 00±0.00 00±0.00
1 24.26±2.14 10.34±1.23 12.71±5.21 13.34±6.12 15.35±1.22 16.24±1.45
2 32.54±3.42 14.56±3.58 15.81±4.13 16.89±5.12 17.35±3.25 19.46±3.12
3 39.35±1.67 20.74±1.45 22.47±2.33 24.46±2.66 23.83±3.45 26.89±8.45
4 46.87±7.18 25.89±4.78 27.85±1.36 31.43±2.22 30.34±2.33 32.64±5.55
5 58.15±6.44 28.61±8.23 31.18±3.45 38.18±9.13 39.49±0.88 38.49±5.61
6 66.89±7.54 35.42±2.43 36.69±4.82 44.67±6.43 47.91±6.65 45.82±3.67
7 74.73±9.45 41.45±6.41 43.68±3.12 51.49±0.98 53.81±4.58 52.91±7.17
8 81.95±1.32 50.32±5.78 47.59±3.54 59.43±2.13 56.84±1.26 61.87±3.21
9 88.65±9.34 57.57±8.34 58.62±1.32 62.87±3.22 60.43±6.33 65.57±2.36
10 92.75±6.32 62.67±5.32 63.65±7.81 65.78±2.44 64.61±1.89 67.66±5.32
*Statistically significant difference in drug release (paired ‘t’ test at p=0.05)
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Stability studies:
For stability studies liposome formulations were stored at 
different temperature such as 4±2 °C, 25±2°C and 37±2°C. 
The maximum % entrapment was observed in 4±2 °C (re-
frigerated) temperature compared to 25±2°C and 37±2°C 
temperature (Table 4). The magnitude of drug retention 
within the vesicles, on storage under defined conditions, 
ultimately governs the shelf life of the developed formula-
tion. Acceleration in drug leakage at higher temperatures, 
as observed in storage-stability studies, suggested keeping 
the liposomal product in the refrigeration conditions, to 
minimize the drug leakage from liposomal-systems. The 
optimized formulation RLP5 shows better storage stability 
at refrigerated condition than other formulations.
Table 4: Stability study of different formulations of baclofen 
liposomes
Formula-
tion Code
Time (month)
1 3 6
Temperature (°C)
4±2
% Entrapment
RLP1 57.61±0.91 56.82±0.34 56.72±0.43
RLP2 57.65±0.82 58.68±0.56 58.62±0.51
RLP3 58.31±0.45 59.98±0.42 60.83±0.67
RLP4 62.22±0.54 61.65±0.31 61.62±0.74
RLP5 64.19±0.26 63.54±0.68 63.45±0.23
25±2
RLP1 46.48±1.36 45.78±0.71 46.56±0.28
RLP2 46.78±0.86 47.67±0.15 48.59±0.61
RLP3 49.67±0.81 50.62±0.43 49.23±0.13
RLP4 55.38±0.46 52.56±0.71 51.34±0.35
RLP5 58.84±0.91 55.52±0.87 53.69±0.41
37±2
RLP1 38.77±0.18 37.89±0.12 37.89±0.71
RLP2 40.88±0.35 39.67±0.24 38.26±0.18
RLP3 41.36±0.78 40.57±0.45 41.91±0.40
RLP4 44.37±0.71 42.51±0.69 43.59±0.51
RLP5 47.74±0.21 46.48±0.58 46.73±0.30
In vivo study:
In vivo study was carried out to check the potential activity 
of formulation, and it was determined by rota-rod appa-
ratus at CT Institute of Pharmaceutical Sciences, Jalandhar 
(Punjab), India. For the in vivo study 45 mice (Mus muscu-
lus) were selected. The dosage regimen was 1 to 4 mg/kg 
for optimized formulation RLP5 and plane drug as per lit-
erature. The plane drug treated (1, 2, 3 and 4 mg/kg) mice 
showed lesser number of falls from rota-rod apparatus in 
comparison to optimized formulation RLP5 (1, 2, 3 and 4 
mg/kg) and diazepam (2 mg/kg), results are given in Ta-
ble 3.1. Similarly optimized formulation RLP5 treated mice 
showed increased number of falls than plane drug treated 
mice but lesser number of falls was observed in case of di-
azepam treated mice. When the dose of optimized formula-
tion was increased (1, 2, 3 and 4 mg/kg) there was increase 
in number of falls from rota-rod apparatus, because lipo-
somal formulation permeated well through the skin and 
absorbed in systemic circulation, and may completely relax 
the muscle. The mice treated with formulations have shown 
improved muscle relaxant activity which was evident by 
increased number of falls in rota-rod test as compared to 
plane drug treated mice. The data pertaining to number of 
falls were analyzed by one way ANOVA followed by Stu-
dent-Newman-Keuls test. The effect of formulation was 
dose dependent (p values are 0.001 for 1, 2, 3 and 4 mg/kg, 
respectively). However, diazepam treated mice may result-
ed higher muscle relaxation than any dose of formulation 
tested (Figure 2).
NOTE: M.D.= Mean deviation
S.D.= Standard deviation
***=P<0.001
Figure 2: Comparison of plane drug, optimized formulation RLP5 
and diazepam on albino mice for skeletal muscle relaxant activity 
(n=6)
CONCLUSIONS
Liposomal formulation containing baclofen possessed 
particle size, particle shape, entrapment efficiency, in vitro 
drug release, stability and in vivo studies and on the basis 
of above these studies revealed that due to small size and 
spherical shape of liposomes gaining access from the epi-
dermal layer of the skin to effectively deliver the baclofen. 
Liposomal formulation releases the baclofen for longer pe-
riod of time in a sustained release manner. Liposomal for-
mulations stable at 4±2°C temperature because in accelerat-
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ed temperature more drug leakage occurs. Baclofen loaded 
liposomal formulation shows skeletal muscle relaxant ac-
tivity performed by rota rod method in mice which could 
deliver the baclofen from liposomes in the therapeutic 
range. For transdermal drug delivery of baclofen via lipos-
omes could deliver and entrap lesser quantity of drug for 
the treatment of spasticity. Finally concluded, the formula-
tion RLP5 of baclofen liposome shows better performance 
than those of respective formulations.
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